ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma
July 26, 2022 01:00 ET | ERC-USA
ISNES, Belgium, July 26, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sitoiganap® (Gliovac...
ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma
June 30, 2022 01:00 ET | ERC-USA
ISNES, Belgium, June 30, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), announced publication of its most recent efficacy data in the May 2022 edition of Frontiers in Oncology. The authors...
ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
April 07, 2021 08:12 ET | ERC-USA
IRVINE, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ERC-USA and the University of California, Irvine (UCI), today announce that the FDA has recommended early termination of the onging Phase 2...
Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting
November 18, 2020 07:00 ET | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Benchmark_logo.jpg
The Benchmark Company, LLC Announces Closing of Initial Public Offering of CNS Pharmaceuticals, Inc.
November 13, 2019 16:30 ET | The Benchmark Company, Llc
NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- The Benchmark Company, LLC today announced the closing of an Initial Public Offering for CNS Pharmaceuticals, Inc. of 2,125,000 shares of common stock at...